Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.

NCT04922788 is registered in ClinicalTrials.gov with Nanogen Pharmaceutical Biotechnology Joint Stock Company as lead sponsor.

NCT NCT04922788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.
Lead sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase
Phase 3
Overall status
Completed
Start date
June 7, 2021
Completion date
July 20, 2022
Enrollment
13,006 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection